Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease
Identifieur interne : 000531 ( Main/Curation ); précédent : 000530; suivant : 000532Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease
Auteurs : Rebecca Stowe [Royaume-Uni] ; Natalie Ives [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Kelly Handley [Royaume-Uni] ; Alexandra Furmston [Royaume-Uni] ; Katherine Deane [Royaume-Uni] ; J. J. Van Hilten [Pays-Bas] ; Keith Wheatley [Royaume-Uni] ; Richard Gray [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2011-03.
English descriptors
Abstract
Background:: Levodopa initially provides good symptomatic control of the symptoms of Parkinson's disease, but motor complications often develop after long‐term use. Other classes of antiparkinsonian drugs including dopamine agonists, catechol‐O‐methyl transferase inhibitors, or monoamine oxidase type B inhibitors are then added as adjuvant therapy. It is unclear whether one class of drug is more effective than another. This meta‐analysis evaluates the comparative benefits and risks of these agents as adjuvant treatment in Parkinson's disease patients with motor complications. Methods:: A systematic review of the literature from 1966 to the end of June 2010 was conducted to identify randomized trials involving a dopamine agonist, catechol‐O‐methyl transferase inhibitor, or monoamine oxidase type B inhibitor versus placebo, as adjuvant to levodopa therapy. Results:: Forty‐five trials involving nearly 9,000 participants were included. The meta‐analysis confirms reports from individual trials that compared with placebo, adjuvant therapy significantly reduces patient off‐time and levodopa dose, with improved symptom severity scores (e.g., Unified Parkinson's Disease Rating Scale). However, dyskinesia and numerous other side effects are increased with adjuvant therapy. Few randomized comparisons between drugs have been undertaken, but indirect comparisons suggest that dopamine agonist therapy may be more effective than catechol‐O‐methyl transferase inhibitor and monoamine oxidase type B inhibitor therapy, which have comparable efficacy. No differences between drugs within each class were observed other than the catechol‐O‐methyl transferase inhibitor tolcapone appearing more efficacious than entacapone. Discussion:: This meta‐analysis highlights the need for direct head‐to‐head randomized trials to assess the impact of adjuvant therapy on patient‐rated quality of life and health economic outcomes. © 2011 Movement Disorder Society
Url:
DOI: 10.1002/mds.23517
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000612
Links to Exploration step
ISTEX:87167D8C859FC5D6666C47A6687F1FEAE2BD9593Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease</title>
<author><name sortKey="Stowe, Rebecca" sort="Stowe, Rebecca" uniqKey="Stowe R" first="Rebecca" last="Stowe">Rebecca Stowe</name>
<affiliation wicri:level="1"><mods:affiliation>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
<affiliation wicri:level="1"><mods:affiliation>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Clarke, Carl E" sort="Clarke, Carl E" uniqKey="Clarke C" first="Carl E." last="Clarke">Carl E. Clarke</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, City Hospital, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neurology, City Hospital, Birmingham</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Handley, Kelly" sort="Handley, Kelly" uniqKey="Handley K" first="Kelly" last="Handley">Kelly Handley</name>
<affiliation wicri:level="1"><mods:affiliation>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Furmston, Alexandra" sort="Furmston, Alexandra" uniqKey="Furmston A" first="Alexandra" last="Furmston">Alexandra Furmston</name>
<affiliation wicri:level="1"><mods:affiliation>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Deane, Katherine" sort="Deane, Katherine" uniqKey="Deane K" first="Katherine" last="Deane">Katherine Deane</name>
<affiliation wicri:level="1"><mods:affiliation>School of Nursing and Midwifery, University of East Anglia, Norwich, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Nursing and Midwifery, University of East Anglia, Norwich</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Van Hilten, J J" sort="Van Hilten, J J" uniqKey="Van Hilten J" first="J. J." last="Van Hilten">J. J. Van Hilten</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Neurology, Leiden University Medical Center, Leiden</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wheatley, Keith" sort="Wheatley, Keith" uniqKey="Wheatley K" first="Keith" last="Wheatley">Keith Wheatley</name>
<affiliation wicri:level="1"><mods:affiliation>Cancer Research UK Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cancer Research UK Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gray, Richard" sort="Gray, Richard" uniqKey="Gray R" first="Richard" last="Gray">Richard Gray</name>
<affiliation wicri:level="1"><mods:affiliation>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:87167D8C859FC5D6666C47A6687F1FEAE2BD9593</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23517</idno>
<idno type="url">https://api.istex.fr/document/87167D8C859FC5D6666C47A6687F1FEAE2BD9593/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">000612</idno>
<idno type="wicri:Area/Main/Curation">000531</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease</title>
<author><name sortKey="Stowe, Rebecca" sort="Stowe, Rebecca" uniqKey="Stowe R" first="Rebecca" last="Stowe">Rebecca Stowe</name>
<affiliation wicri:level="1"><mods:affiliation>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ives, Natalie" sort="Ives, Natalie" uniqKey="Ives N" first="Natalie" last="Ives">Natalie Ives</name>
<affiliation wicri:level="1"><mods:affiliation>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Clarke, Carl E" sort="Clarke, Carl E" uniqKey="Clarke C" first="Carl E." last="Clarke">Carl E. Clarke</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, City Hospital, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neurology, City Hospital, Birmingham</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Clinical and Experimental Medicine, College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Handley, Kelly" sort="Handley, Kelly" uniqKey="Handley K" first="Kelly" last="Handley">Kelly Handley</name>
<affiliation wicri:level="1"><mods:affiliation>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Furmston, Alexandra" sort="Furmston, Alexandra" uniqKey="Furmston A" first="Alexandra" last="Furmston">Alexandra Furmston</name>
<affiliation wicri:level="1"><mods:affiliation>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Deane, Katherine" sort="Deane, Katherine" uniqKey="Deane K" first="Katherine" last="Deane">Katherine Deane</name>
<affiliation wicri:level="1"><mods:affiliation>School of Nursing and Midwifery, University of East Anglia, Norwich, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>School of Nursing and Midwifery, University of East Anglia, Norwich</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Van Hilten, J J" sort="Van Hilten, J J" uniqKey="Van Hilten J" first="J. J." last="Van Hilten">J. J. Van Hilten</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands</mods:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Neurology, Leiden University Medical Center, Leiden</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Wheatley, Keith" sort="Wheatley, Keith" uniqKey="Wheatley K" first="Keith" last="Wheatley">Keith Wheatley</name>
<affiliation wicri:level="1"><mods:affiliation>Cancer Research UK Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Cancer Research UK Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Gray, Richard" sort="Gray, Richard" uniqKey="Gray R" first="Richard" last="Gray">Richard Gray</name>
<affiliation wicri:level="1"><mods:affiliation>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham, United Kingdom</mods:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Birmingham Clinical Trials Unit, College of Medical & Dental Sciences, University of Birmingham, Edgbaston, Birmingham</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-03">2011-03</date>
<biblScope unit="volume">26</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="587">587</biblScope>
<biblScope unit="page" to="598">598</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">87167D8C859FC5D6666C47A6687F1FEAE2BD9593</idno>
<idno type="DOI">10.1002/mds.23517</idno>
<idno type="ArticleID">MDS23517</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term>
<term>adjuvant treatment</term>
<term>levodopa</term>
<term>meta‐analysis</term>
<term>motor complications</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background:: Levodopa initially provides good symptomatic control of the symptoms of Parkinson's disease, but motor complications often develop after long‐term use. Other classes of antiparkinsonian drugs including dopamine agonists, catechol‐O‐methyl transferase inhibitors, or monoamine oxidase type B inhibitors are then added as adjuvant therapy. It is unclear whether one class of drug is more effective than another. This meta‐analysis evaluates the comparative benefits and risks of these agents as adjuvant treatment in Parkinson's disease patients with motor complications. Methods:: A systematic review of the literature from 1966 to the end of June 2010 was conducted to identify randomized trials involving a dopamine agonist, catechol‐O‐methyl transferase inhibitor, or monoamine oxidase type B inhibitor versus placebo, as adjuvant to levodopa therapy. Results:: Forty‐five trials involving nearly 9,000 participants were included. The meta‐analysis confirms reports from individual trials that compared with placebo, adjuvant therapy significantly reduces patient off‐time and levodopa dose, with improved symptom severity scores (e.g., Unified Parkinson's Disease Rating Scale). However, dyskinesia and numerous other side effects are increased with adjuvant therapy. Few randomized comparisons between drugs have been undertaken, but indirect comparisons suggest that dopamine agonist therapy may be more effective than catechol‐O‐methyl transferase inhibitor and monoamine oxidase type B inhibitor therapy, which have comparable efficacy. No differences between drugs within each class were observed other than the catechol‐O‐methyl transferase inhibitor tolcapone appearing more efficacious than entacapone. Discussion:: This meta‐analysis highlights the need for direct head‐to‐head randomized trials to assess the impact of adjuvant therapy on patient‐rated quality of life and health economic outcomes. © 2011 Movement Disorder Society</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000531 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000531 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonV1 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:87167D8C859FC5D6666C47A6687F1FEAE2BD9593 |texte= Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |